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We have previously identified a human CD8+HLA-DR+ regulatory T cell subset with the
ability to suppress proliferation of autologous PBMCs responder cells through cell contact
and CTLA-4 co-inhibitory molecule. The present study characterizes the complete
phenotype of CD8+HLA-DR+ Treg cells which showed great similarities with classical
CD4+ cells expressing forkhead box P3 (FOXP3). The shared features included the
expression of programmed cell death protein 1 (PD-1), T-cell immunoreceptor with Ig
and ITIM domains (TIGIT), C-C chemokine receptor type 4 and 5 (CCR4 and CCR5),
low expression of CD127, and a memory and effector-like phenotype. CD8+HLA-DR+
Treg-induced suppression on CD8+ responder T cells was abrogated by an anti-PD1
neutralizing antibody. Anti-PD-1 did not abrogate the suppressor effect induced on
responder CD4+ T cells. In addition, CD8+HLA-DR+ Treg induced a preferential death
on responder CD8+ T cells. This effect was not reversed by PD-1 neutralization. After
activation, most CD8+HLA-DR+ Treg acquire programmed death-ligand 1 (PD-L1)
expression. Interestingly, PD-L1 may induce apoptosis through CD80 expressed on
activated CD8+ responder T cells. After PBMCs stimulation, CD8+HLA-DR+ Treg
cells showed an increased frequency of IFN-γ and TNFα positive cells and higher
degranulation. These data strongly argue against CD8+HLA-DR+ Treg being exhausted
cells. Overall, the data presented in this study indicate that CD8+HLA-DR+ Treg and
CD4+FOXP3+ Treg share phenotypic and functional features, which may provide cues
to similar involvements in the control of antitumor immune responses and autoimmunity.
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INTRODUCTION
Regulatory T cells (Treg) play a key role in maintaining immune
homeostasis and in preventing the onset of autoimmune
diseases (1). Although several subsets of Treg have been
described, the best characterized is defined by expression
of CD4, CD25, and the transcription factor forkhead box
P3 (FOXP3) (2). Most circulating CD4+FOXP3+ Treg
originate in the thymus (tTreg). However, naïve CD4+ T
cells may also be induced to express FOXP3 in the periphery,
representing a minority (pTreg) population (3) required for fetal
tolerance (4).
We recently described a novel human regulatory CD8+HLA-
DR+ T cell population present in adult and umbilical
venous blood samples (5) representing a small subset in
peripheral blood (PB) or cord blood mononuclear cells
(CBMCs). The comparison between CD8+HLA-DR− and
CD8+HLA-DR+ T cells shows similar expression of the co-
stimulatory molecule CD28, which differentiates them from
the previously characterized CD8+CD28−/low T suppressor
cells originally generated in vitro by multiple rounds of
T cell stimulation by allogenic APCs (6). Another natural
CD8+ Treg population distinguished by expression of CD122
(7) was described in mice, but has not yet been identified
in humans, and appear to exert their suppressor effect via
IL-10.
The presence of CD8+HLA-DR+ Treg in cord blood
strongly suggests that these Treg most likely originate from
thymic emigrants and gradually increase over time. Their
expansion is presumably induced through an encounter
with environmental or self-antigens that generate the
memory-like phenotype observed in adult CD8+HLA-DR+
Treg.
In the control of peripheral T-cell tolerance and
autoimmunity, checkpoint pathways involving particularly
cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) and
programmed death 1 (PD-1) are thought to operate at different
stages of an immune response (8), CTLA-4 acting at the initial
stage of naïve T-cell activation, typically in lymph nodes (9).
PD-1 pathway regulates previously activated T cells at later
stages of immune response, primarily in peripheral tissues
(8). Similarities and differences in these pathways have greatly
contributed to cancer therapy involving immune checkpoint
blockade (ICB).
In our previous study we identified features shared between
CD8+HLA-DR+ Treg and classical CD4+FOXP3+ Treg cells;
these included the requirement for cell-to-cell contact mainly
involving CTLA-4, and complete abrogation of suppressor
capacity by blocking this B7 ligand. In the present study
we expanded phenotypic and functional characterization of
CD8+HLA-DR+ Treg cells, including the complete phenotype
of the CD8+HLA-DR+ Treg cells, their developmental
stage, their exhaustion status, and similarities with canonical
CD4+FOXP3+ Treg cells. In addition, we demonstrated
that anti-PD-1 selectively abrogates the suppressor effect
on CD8+ effector cells without affecting CD4+ effector
cells.
MATERIALS AND METHODS
Ethics Statement
This study was approved by the Investigation and Ethics
Committee at the Hospital de Clínicas “Jose’ de San Martin” and
Hospital de Pediatría S.A.M.I.C. “Prof. Dr. Juan P. Garrahan” in
accordance with the Declaration of Helsinki.
Subjects
Peripheral blood (PB) mononuclear cells were obtained from
healthy adult donors (HD), and cord blood (CB) samples
from umbilical cord veins of full-term healthy neonates.
None of the HD, neonates, or their mothers had any
hereditary disorders, hematologic abnormalities, or infectious
complications.
Peripheral Blood and Cord Blood
Mononuclear Cell Isolation
Freshly isolated PBMCs or CB mononuclear cells were isolated
through Ficoll-Hypaque gradient centrifugation (GE Healthcare
Life Sciences). After two washes with PBS, cells were suspended
in RPMI medium.
Antibodies, Flow Cytometry, and Analysis
of Cytokine Production
Isolated peripheral and cord blood mononuclear cells
were incubated for 15min at room temperature (RT) with
fluorescence-conjugated mAbs purchased from the following
sources: Biolegend: anti-CD3 (PerCP or Pacific Blue), anti-CD8
(APC-Cy7 or PerCP), anti-HLA-DR (FITC, PE or Brilliant
Violet 421), anti-CD45RA (PE-Cy7), anti-CD27 (PE-Texas
Red), anti-CD28 (PE or Brilliant Violet 711), anti-CCR7 (FITC
or Brilliant Violet 785), anti-CCR5 (PE-Cy7), anti-CXCR3
(FITC), anti-CCR4 (Brilliant Violet 421), anti-PD-1 (PE or
Brilliant Violet 711), anti-PD-L1 (APC), anti-CD155 (PE-
Cy7), anti-Eomes (PE-Cy7), anti-CD127 (PE), anti-IFN-γ
(PE-Cy7), anti-TNFα (Brilliant Violet 711), anti-CD107a (PE
or FITC), anti-Ki-67 (PE or FITC). eBiosciences: anti-TIM-3
(APC), anti-CTLA-4 (PE), anti-TIGIT (PerCPeFluor710).
Immunotools: anti-CD8 (APC), anti-HLA-DR (PE), anti-
Granzyme B (FITC). For intranuclear staining, PBMCs were
fixed and permeabilized with FOXP3 / Transcription Factor
Fixation/Permeabilization Concentrate and Diluent solution
(eBioscience) following the manufacturer’s instructions. Anti-
Ki-67 Ab was incubated after permeabilization. To detect
intracellular cytokines, PBMCs were activated with PMA
(50 ng/mL) and Ionomycin (1µg/mL) for 4 h in the presence of
monensin (Golgi stop-BD Biosciences). Alternatively, PBMCs
were activated with plate-coated anti-CD3 (1µg/mL) and soluble
anti-CD28 (1µg/mL). Anti-CD107a was added during in vitro
stimulation to detect degranulation. After permeabilization
using the BD Cytofix/Cytoperm Fixation/Permeabilization
Kit (BD Biosciences), anti-IFN-γ, anti-TNFα, anti-CTLA-4,
and anti-Granzyme B were added. LIVE/DEAD R© Fixable
Aqua (Thermofisher) or 7AAD (BD Biosciences) were
used to exclude dead cells. The gating strategy is depicted
in Figure S1. Flow cytometry was performed using FACS
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Aria IIu (BD Biosciences), and data analyzed using FlowJo
software.
Cell Sorting
Fresh peripheral blood CD8+ T cells from healthy donors were
enriched by negative selection using the RosetteSep Human
CD8+ T Cells Enrichment Cocktail (StemCell Technologies)
following manufacturer’s protocol. Purified CD8+ T cells were
stained with anti-CD8 APC and anti-HLA-DR PE antibodies
(Immunotools) and sorted with a FACS Aria IIu flow cytometer
(BD Biosciences), obtaining the following subsets: CD8+HLA-
DR+ and CD8+HLA-DR−. Both subsets were collected into
complete RPMI 1640 medium containing 50% FCS and washed
before further experiments. The purity of each population,
determined by flow cytometry, was always over 95%. For
CD8+ cells depletion, peripheral blood mononuclear cells
from healthy donors were isolated by density gradient,
and CD8+ lymphocytes were depleted after staining with
anti-CD8 APC (Immunotools). CD8+ depletion was ∼99%
effective.
Suppression Assay
Responder autologous PBMCs were labeled with 5µM of
CellTrace Violet (ThermoFisher) following manufacturer’s
protocol. 5 × 104 responder cells were plated on 96 round-
bottom wells and co-cultured in complete RPMI 1640 medium
[Life Technologies] (supplemented with penicillin, streptomycin,
L-glutamine [Sigma-Aldrich], and 10% FCS [Natocor]) with
unlabeled highly purified CD8+HLA-DR+ or CD8+HLA-DR-
T cells in a responder: suppressor ratio of 1:1. Cells were
stimulated with 1µg/mL of plate-coated CD3 (Biolegend)
and 1µg/mL of soluble CD28 (Biolegend). On day 4 post-
activation, cells were harvested, and proliferation of CellTrace
Violet-labeled cells was assessed by flow cytometry. At this
time point, cells were stained with anti-human CD3 FITC
(Immunotools), anti-human CD4 BV605 (Biolegend) and
anti-human CD8 APC (Immunotools), and incubated with
7-AAD (BD Bioscience) to analyze cytotoxicity and exclude
dead cells. Percentage of suppression was calculated by dividing
the number of proliferating CellTrace Violet-diluting responder
cells in the presence of suppressor cells by the number of
proliferating responder cells when cultured alone, multiplied by
100. Unlabeled, stimulated, and unstimulated cells were used as
controls.
Neutralizing Assay
To investigate neutralizing the suppressor effect, purified
anti-PD-1 antibody (0.5 and 1µg/mL; Biolegend) was
added in the same culture conditions described for the
suppression assay above, using the corresponding isotype-
matched mAb as control. Purified PD-L1 neutralizing antibody
(Biolegend) was used at 5µg/mL. To test involvement of
CTLA-4 added together with anti-PD-1 in the suppression
mechanism, 5µg/mL of anti-CTLA-4 (BD Biosciences) was
used.
Co-culture of CD8+-Depleted PBMCs With
Highly Purified CD8+HLA-DR− or
CD8+HLA-DR+ Cells
Autologous 5 × 105 CD8+-depleted PBMCs were plated on 48
multiwell plates in complete RPMI medium, and co-cultured
with highly purified 0.9 × 105 CD8+HLA-DR− (5.5: 1), or
0.1 × 105 CD8+HLA-DR+ (50: 1) T cells (the number of
cells were defined according to their relative frequencies within
PBMCs). Cells were activated with plate-coated aCD3 (1µg/mL;
Biolegend) plus soluble aCD28 (1µg/mL; Biolegend). On day
4 post-activation, cells were harvested, and surface HLA-DR
and intra-cellular Ki-67 were assessed by flow cytometry.
Dead cells were excluded using LIVE/DEAD R© Fixable Aqua
(Thermofisher). Unstimulated cultures were used as negative
controls.
Activation of PBMCs and CBMC
Peripheral Blood (PB) or Cord Blood (CB) mononuclear cells
were activated with plate-coated anti-CD3 (1µg/mL) plus
soluble anti-CD28 (1µg/mL). In both cases, 5 × 105 cells were
plated on 48 multiwell plates in complete RPMI medium. For
PBMCs kinetics experiments, cells were stained on day 4 after
activation. For CB samples, cells were stained on day 2 after
activation.
Statistical Analysis
The normality of variable distribution was assessed by the
Kolmogorov- Smirnov goodness-of-fit test. Once the hypothesis
of normality was accepted (p = 0.05), comparisons were
performed using paired and unpaired Student t-tests, as
appropriate. If the hypothesis of normality was rejected, analysis
was performed usingWilcoxon’s rank-sum test. A p-value of 0.05
was considered significant.
RESULTS
CD8+ T Cells Expressing HLA-DR Identified
Regulatory T Cells Expressing the
Checkpoint Molecules CTLA-4 and PD-1
We first analyzed phenotypic markers previously associated with
regulatory subsets. For instance, PD-1 and TIGIT are known
to be expressed in classical FOXP3+ Treg (10–12), the IL-
7 receptor (CD127) is broadly used to isolate CD4+FOXP3+
Treg, and CXCR3, CCR5, and CCR4 are present in Treg
cells in peripheral tissues: CD4+CD25+FOXP3+ (13, 14), and
CD4+Tr1+ (15, 16). Considering that HLA-DR is used as
an activation marker, we also analyzed TIM-3 and PD-L1
molecules. Compared to CD8+HLA-DR− T cells, our results
showed a higher frequency of PD-1 (p < 0.0001) and TIGIT
(p < 0.0001), and down-modulation of CD127 frequency (p
= 0.0009) (Figures 1A,B). In addition to increased frequency,
PD-1 expression was also significantly higher (p = 0.0003)
as reflected by increased mean fluorescence intensity (MFI).
CD127 MFI was also lower in CD8+HLA-DR+ Treg than in
CD8+HLA-DR− cells (p = 0.0031) (Figure 1C). Interestingly,
the frequencies of CCR5 (p < 0.0001) and CCR4 (p =
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FIGURE 1 | Phenotypic characterization of CD8+HLA-DR+ Treg and CD8+HLA-DR− cells. (A) PBMC from healthy donors were isolated by density gradient, stained,
and analyzed by flow cytometry. Dot plots are gated on total CD8+ T cells. (B) Graph shows comparative frequency of each molecule gated on CD8+HLA-DR− and
CD8+HLA-DR+ subsets. (C) Mean fluorescence intensity (MFI) of PD-1 and CD127 expression. Data is presented as mean ± SEM of PD-1 (n = 17), CXCR3 (n = 5),
CCR5 (n = 15), CCR4 (n = 7), PD-L1 (n = 5), TIGIT (n = 13), TIM-3 (n = 5), CD127 (n = 6). Paired t-test. **p < 0.01; ***p < 0.001; ****p < 0.0001.
0.0038), were greatly increased in CD8+HLA-DR+ Treg cells
(Figures 1A,B).
Naïve Cord Blood CD8+HLA-DR+ T Cells
Rapidly Acquired the Phenotype of Mature
Peripheral Blood CD8+HLA-DR+ Treg Cells
After Activation
In basal conditions, cord blood (CB) CD8+HLA-DR− and
CD8+HLA-DR+ subsets showed a naïve phenotype, with low
frequency of PD-1, TIGIT, and CTLA-4 (<10%), and more
than 90% of cells from both subsets expressed the CD127
receptor (Figures 2A,B). Despite these similarities, compared
to their CD8+HLA-DR− counterpart, CD8+HLA-DR+ Treg
showed a slightly but significantly increased number of cells
expressing PD-1 (p = 0.0079), TIGIT (p = 0.0079), and
CTLA-4 (p = 0.0003) (Figure 2B). Because we previously
observed that cord blood CD8+HLA-DR+ Treg were able
to suppress responder cell proliferation, we analyzed the
expression kinetics of relevant molecules for suppression after
activation by anti-CD3 plus anti-CD28 antibodies. As depicted
in Figures 2B,C, as soon as 2 days after activation, CB
CD8+HLA-DR+ acquired a phenotype similar in frequency to
the one observed in mature peripheral blood CD8+HLA-DR+
Treg, including sharply decreased frequency of CD127 (p =
0.0002), increased frequency of PD-1 (p = 0.01), TIGIT (p
= 0.0084), and CTLA-4 (p = 0.02), and preservation of the
naïve phenotype. The ability of CB CD8+HLA-DR+ to rapidly
acquire these regulatory molecules may explain the suppressor
capacity of ex vivo CB CD8+HLA-DR+ we previously reported
(5).
We also analyzed the developmental stage of CD8+HLA-
DR− and CD8+HLA-DR+ cells in peripheral blood (PB)
and cord blood (CB) mononuclear cells. Meanwhile PB
CD8+HLA-DR− cells showed a higher frequency of naïve
cells (CD45RA+CCR7+CD27+CD28+) (p < 0.0001), most
CD8+HLA-DR+ Treg have an increased number of late
differentiated cells (CD45RA+CCR7−CD27−CD28−) (p =
0.0317), memory (CD45RA−CCR7+/−CD27+CD28+) (p <
0.0001), and effector (CD45RA−CCR7−CD27−CD28−) (p =
0.0003) (Figures 3A,B). Conversely, as expected, the frequency
of late differentiated, memory and effector T cells within cord
blood were almost undetectable, being mostly CD8+HLA-DR−
and CD8+HLA-DR+ naïve cells (Figures 3A,B).
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FIGURE 2 | After TCR activation, cord blood CD8+HLA-DR+ Treg cells acquire a peripheral blood-like phenotype. (A) Representative dot plots show PD-1, TIGIT,
CD127 and CTLA-4 expression after CB mononuclear cells activation for 2 days with plate-coated aCD3 (1µg/mL) and soluble aCD28 (1µg/mL). Analysis was
performed on gated CD8+ cells at day 0 (Upper) and day 2 after activation (Lower). (B) Comparative frequency of PD-1, TIGIT, CD127 and CTLA-4 gated on
CD8+HLA-DR− and CD8+HLA-DR+ subsets, and presented as mean frequency ± SEM from six independent experiments. (C) Comparative frequency of CB and
PB PD-1, TIGIT, CD127 and CTLA-4 on day 2 after activation (gated on each CD8 subset). Paired or unpaired t-test. *p < 0.05; **p < 0.01; ***p < 0.001.
Immunosuppressive Properties of
CD8+HLA-DR+ Treg Cells Are Associated
With PD-1 Molecule
Previously we reported the involvement of CTLA-4 in the
suppressor mechanism of these cells (5). Given the high
frequency and expression of PD-1 on CD8+HLA-DR+ Treg,
we investigated the effect of an anti-PD-1 neutralizing antibody
on the suppressor activity of this subset. We assessed the
in vitro suppressive capacity of purified CD8+HLA-DR− and
CD8+HLA-DR+ T cells by diluting CellTrace Violet-labeled
autologous PBMCs (hereafter called responder cells) co-cultured
with each CD8+ T cell subset, and stimulated for 4 days with
anti-CD3 plus anti-CD28 antibodies. Purified CD8+HLA-DR+
Treg were able to suppress the proliferative response of activated
responder cells (Figure 4A). Anti-PD-1 antibody at 1µg/mL
fully abrogates the suppressor effect of CD8+HLA-DR+ Treg
cells (p = 0.0015) (Figure 4B; Table 1). Similarly, an anti-PD-
L1 neutralizing antibody induces the same effect (Figure S2). To
further analyze the potential target population, we investigated
the effect of adding CD8+HLA-DR+ to gated CD4+ or CD8+
CellTrace Violet-labeled responder cells. Addition of CD8+HLA-
DR+ induced a decrease of over 50% in the proliferative capacity
of CD4+ responder T cells and a relatively lower proliferative
capacity of responder CD8+ cells. Strikingly, anti-PD-1 antibody
only abrogates the suppressor effect induced on CD8+ responder
cells (p = 0.0192) (Figure 4C; Table 2). To elucidate if the
different suppressor behavior over CD8+ and CD4+ responder
cells was associated to their PD-1 and PD-L1 expression, we
analyzed the kinetics of these molecules on days 0 and 4
during the suppression culture. We observed that after activation
PD-1 and PD-L1 increased in a similar way on both CD8+
and CD4+ responder cells (Figure S3). As also depicted in
the same figure, CTLA-4 behaved similarly to PD-1 and PD-
L1 on both responder subsets. These results suggest that the
different effect observed on CD8+ and CD4+ responder cells is
independent of their PD-1 or PD-L1 expression. However, when
anti-CTLA-4 was added together with anti-PD-1, the suppressor
effect on CD4+ responder cells was also abrogated (Figure S4).
All together, these results suggest that CD8+HLA-DR+ Treg
suppress both CD4+ and CD8+ responder populations, but only
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FIGURE 3 | Differences in maturation status detected in CD8+HLA-DR− and CD8+HLA-DR+ Treg cells from adult peripheral blood (PB) or cord blood (CB).
(A) Representative dot plots show the expression of CD45RA vs. CCR7, and CD28 vs. CD27 used herein to define the maturation stage of peripheral blood (n = 13)
(Left) and cord blood mononuclear cells (n = 6) (Right). Arrows indicate the sequence of the analysis. (B) Shows comparative frequency of each maturation stage
between CD8+HLA-DR− and CD8+HLA-DR+ in PB (n = 13) and CB (n = 6). Data is presented as mean frequency ± SEM. Paired and unpaired t-test were used
when comparing results from the same donor or comparing PB and CB samples, respectively. *p < 0.05; ***p < 0.001; ****p < 0.0001.
CD8+ proliferation is downregulated through PD-1 molecule
expressed on CD8+HLA-DR+ Treg. However, the combined
addition of both anti-PD-1 and anti-CTLA-4 were able to
suppress also CD4+ responder cells. Of note, the addition of
sorted CD8+HLA-DR+ (but not CD8+HLA-DR−) induced 37
± 6.5% of 7AAD+ cells within responder CD8+ cells (p =
0.0327), with no significant effect on CD4+ cells. This effect
was not reversed by the addition of the anti-PD-1 antibody
(Figure 4D).
When PBMCs were stimulated for 4 days with anti-
CD3 plus anti-CD28, and proliferation measured by Ki-
67 expression, we observed that CD8+HLA-DR+ Treg cells
showed a much stronger proliferative response (Figure 5A).
Within these Ki-67+ proliferative cells, we detected the
co-expression of PD-1 (Figure 5B). This co-expression was
observed in 40 ± 15% of CD8+HLA-DR+ Treg. During
the suppressor assay we also utilized 7-AAD to discriminate
between dead and viable cells within the CellTrace Violet-
negative sorted CD8+HLA-DR− or CD8+HLA-DR+. Increased
frequency of non-viable cells was detected in sorted CD8+HLA-
DR+ cells: 40 vs. 5% in CD8+HLA-DR− (irrespective of
the ratio of responder and sorted CD8 cells; Figure 5C).
These results suggest that CD8+HLA-DR+ Treg have an
elevated renewal rate (high proliferation rate and high death
rate).
Expression of HLA-DR on Highly Purified
CD8+HLA-DR− And CD8+HLA-DR+ Cells
To assess the stability of CD8+HLA-DR+ Treg cells, CD8+-
depleted PBMCs were co-cultured with highly purified
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FIGURE 4 | Immunosuppressive properties of CD8+HLA-DR+ Treg. Autologous PBMC labeled with CellTrace Violet were used as responder cells. CD8+HLA-DR−
and CD8+HLA-DR+ sorted cells were cultured with 5 × 104 PBMC in a 1:1 ratio (suppressor: responder). After 4 days’ activation with aCD3/aCD28 (1µg/mL)
proliferation was measured by CellTrace Violet dilution. (A) Representative dot plots from gated CD3+ cells showing the role of anti-PD-1 in reversing suppressor
capacity of CD8+HLA-DR+ Treg cells. (B) Shows mean frequency of suppression induced by CD8+HLA-DR+ Treg and the reversion effect after addition of
anti-PD-1 antibody (n = 5). (C) Similar to the analysis performed in (B) but analyzed on gated CD4+ or CD8+ T cells (n = 4). (D) Shows mean frequency of 7AAD
positive cells at day 4 of the suppression assay (n = 5). Data is presented as mean ± SEM. Paired t-test. *p < 0.05; **p < 0.01.
TABLE 1 | CD8+HLA-DR+ Treg mechanism of action.
Suppression
(Average ± SEM)
CD8+HLA-DR− (1:1) 2.9 ± 2.5
CD8+HLA-DR− (1:1)
+ aPD-1 (1µg/mL)
−3.4 ± 5.1
CD8+HLA-DR+ (1:1) 35 ± 3.4
CD8+HLA-DR+ (1:1)
+ aPD-1 (1µg/mL)
−7 ± 3.8
CD8+HLA-DR− or CD8+HLA-DR+ cells. Additionally,
HLA-DR and Ki-67 expression were evaluated after 4 days
activation with anti-CD3 plus anti-CD28. Meanwhile 34% of
CD8+HLA-DR− cells acquire the HLA-DR molecule, almost
all CD8+HLA-DR+ Treg cells remain HLA-DR+ (87%).
Notably, when CD8+HLA-DR− subset were co-cultured
with the CD8+-depleted PBMCs 41% acquired Ki-67, that
contrasted with the acquisition of Ki-67 by 80% of the
CD8+HLA-DR+ cells (Figure 6). These results suggest that a
TABLE 2 | Suppression effect of CD8+HLA-DR+ Treg cells on CD4+ and CD8+
target cells.
Suppression
(Average ± SEM)
on target CD4+ T cells
Suppression
(Average ± SEM)
on target CD8+ T cells
CD8+HLA-DR+ (1:1) 51 ± 5.3 33.4 ± 6.5
CD8+HLA-DR+ (1:1)
+ aPD-1 (1µg/mL)
42 ± 7 −4 ± 9.2
subpopulation of CD8+HLA-DR+ Treg cells can be induced
from CD8+HLA-DR− after TCR activation.
CD8+HLA-DR+ Treg Cells Are Not
Exhausted T Cells
The expression of PD-1, TIGIT and TIM-3 has been associated
with exhausted cells (17, 18). As described in the previous section,
CD8+HLA-DR+ Treg have an elevated renewal rate. Analysis
of CD8+HLA-DR+ Treg within PMA/Ionomycin stimulated
PBMCs showed that they had an increased number of cells
Frontiers in Immunology | www.frontiersin.org 7 November 2018 | Volume 9 | Article 2788
Machicote et al. CD8+HLA-DR+ Tregs Act via PD-1/PD-L1
FIGURE 5 | CD8+HLA-DR+ Treg have a high renewal rate. PBMC from healthy donors isolated by density gradient were activated with plate-coated aCD3 (1µg/mL)
and soluble aCD28 (1µg/mL). Surface PD-1 and intracellular Ki-67 were stained on day 0 and 4 after activation. Ten minutes before reading the tubes in the flow
cytometer, 7AAD death marker was added to the samples. (A) Mean frequency of Ki-67 on CD8+HLA-DR− and CD8+HLA-DR+ cells after activation (n = 7).
(B) Representative dot plots show the co-expression of PD-1 and Ki-67 gated on CD8+HLA-DR− and CD8+HLA-DR+ subsets (n = 7). (C) Shows mean frequency
of 7AAD 4 days after activation on sorted CD8+HLA-DR− and CD8+HLA-DR+ cells, cultured with autologous PBMC (n = 5). Paired or unpaired t-test. *p < 0.05;
**p < 0.01.
expressing IFN-γ (p = 0.0098), TNFα (p = 0.0004), and
CD107a (p = 0.0006). Moreover, no differences in secretion
levels of granzyme B were detected when CD8+HLA-DR− and
CD8+HLA-DR+ subsets were compared (Figures 7A,B). Apart
from their capacity to secrete cytokines and degranulate, these
cells lack expression of the terminally exhausted marker TIM-3
(Figure 1A).
Given that PD-1 ligation can antagonize CD3 signaling,
we evaluated the capacity of these Treg to secrete IFN-γ
and degranulate in response to anti-CD3 plus anti-
CD28 stimulation. Similarly to PMA/Ionomycin stimuli,
a higher frequency of CD107a (p = 0.0178) and IFN-γ
(p = 0.095) cells was observed in CD8+HLA-DR+ cells
than in CD8+HLA-DR− (Figure S5), suggesting that
CD8+HLA-DR+ Treg are capable of responding to TCR
ligation.
In basal conditions, total CD8+ T cells lack expression of
PD-1 ligand 1 (PD-L1) and TIGIT ligand CD155. To mimic
suppression assay conditions, PBMCs were activated with anti-
CD3 plus anti-CD28, and PD-L1 and CD155 expression was
evaluated on day 4 after activation. A higher frequency of both
receptors (p = 0.0007 and p = 0.0008, respectively) was detected
in activated CD8+HLA-DR+ Treg cells than in their CD8+HLA-
DR− counterpart (Figures 8A,B).
DISCUSSION
In our previous work (5) we showed that human CD8+HLA-
DR+ but not CD8+HLA-DR− cells suppress proliferation
of autologous PBMCs responder cells through CTLA-4 co-
inhibitory molecule. Our present data further characterize this
regulatory subset by identifying a wide array of molecules
showing preferential expression within CD8+HLA-DR+ Treg
over CD8+HLA-DR− cells. The complete phenotype includes,
in addition to CTLA-4, expression of checkpoint receptors
PD-1 and TIGIT and increased frequency of CCR4 and
CCR5 chemokine receptors. Strikingly, this phenotype profile
shared most of the molecules expressed by a subpopulation
of CD4+FOXP3+ Treg cells with stronger regulatory capacity
than conventional CD4+FOXP3+ Treg (11, 19). Low expression
of CD127 and memory and effector-like phenotype are other
features also shared by CD8+HLA-DR+ and CD4+FOXP3+
Treg cells (20).
Umbilical cord blood (CB) is a source of immature
lymphocytes. CB CD8+ T cells are predominantly naïve cells
defined by their CD45RA+CCR7+CD27+CD28+ co-expression.
Concordantly with the similar naïve stage, both subsets showed
low or absent frequency of CTLA-4, TIGIT and PD-1 molecules
and high frequency of IL-7 receptor CD127. However, after only
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FIGURE 6 | Stable expression of HLA-DR on in vitro activated CD8+HLA-DR+ Treg cells. PBMCs from healthy individuals were isolated, stained, and the following
populations were purified in a FACS Aria II cell sorter: CD8+-depleted mononuclear cells, CD8+HLA-DR− and CD8+HLA-DR+ subsets. (A) Dot plots show the purity
of each population after sorting. (B) 5 × 105 CD8+-depleted PBMCs were culture alone, or co-culture with purified 0.9 × 105 CD8+HLA-DR− or 0.1 × 105
CD8+HLA-DR+ cells. On day 4 after aCD3 (1µg/mL)/aCD28 (1µg/mL) activation, surface HLA-DR and intra-cellular Ki-67 were stained. Singlets were excluded and
living cells were selected by gating Live/Dead Aqua Fixable death marker-negative cells. HLA-DR and Ki-67 molecules were analyzed within gated CD8+ T cells.
2 days of TCR stimulation, cord blood CD8+HLA-DR+ cells
rapidly acquired a phenotype quite similar to peripheral blood
CD8+HLA-DR+ Treg cells.
The role of CTLA-4 as a mediator of suppressor function
within classical CD4+FOXP3+ Treg cells is well known, as well as
its capacity to negatively regulate immune responses (21). CTLA-
4 is constitutively expressed in CD4+FOXP3+ Treg, probably
because this molecule is a target of FOXP3 transcriptional factor
(22). In contrast with the constitutive expression of PD-1 and
TIGIT on CD8+HLA-DR+ Treg cells, CTLA-4 is induced after T
cell activation, preferentially restricted to CD8+ cells expressing
HLA-DR. Interestingly, and unlike PB CD8+HLA-DR+ Treg,
umbilical CB CD8+HLA-DR+ showed augmented frequency
of CTLA-4 in basal conditions, which may be explained by
the slightly increased level of FOXP3 detected in CB HLA-
DR+ Treg cells (5). Regarding PB CD8+HLA-DR+ Treg, our
previous work showed that the regulatory effect is exerted by
CTLA-4, and requires cell-cell contact. Therefore, blocking of
CTLA-4 abrogated its suppressive effect in a dose-dependent
manner (5).
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FIGURE 7 | CD8+HLA-DR+ Treg are functionally competent cells. PBMC isolated by density gradient were stimulated for 4 h with PMA/Ionomycin in the presence of
monensin. CD107a, IFN-γ, TNFα, and Granzyme B were stained and analyzed by flow cytometry. (A) Dot plots from one representative experiment showing
expression of CD107a and IFN-γ (Left), TNFα and Granzyme B (Right) within CD8+HLA-DR− and CD8+HLA-DR+ cells. (B) Graph shows the comparative frequency
of each molecule gated on CD8+HLA-DR− and CD8+HLA-DR+ subsets (n = 7). Data is presented as mean frequency ± SEM. Paired t-test. **p < 0.01;
***p < 0.001.
FIGURE 8 | Increased expression of PD-1 and TIGIT ligands (PD-L1 and
CD155) after T cell activation. Four days after PBMC activation, PD-L1 and
CD155 were stained and analyzed by flow cytometry. (A) Representative dot
plots show co-expression of HLA-DR, PD-L1 and CD155 gated on total CD8+
T cells on day 0 (Upper) and day 4 after activation (Lower). (B) Frequency of
PD-L1 and CD155 gated on CD8+HLA-DR− and CD8+HLA-DR+ subsets
detected before and after 4 days’ activation. Each point corresponds to an
independent experiment (n = 7). Paired t-test. ***p < 0.001.
PD-1 was first identified in 1992 (23). Initially it was believe
that PD-1 triggered an inhibitory signal for CD3 signaling (24–
26). Recent data support that CD28 costimulatory signaling is
interrupted after PD-1 engagement rather than CD3 (27, 28),
indicating that PD-1 suppresses T cell function primarily by
inactivating CD28 signaling, playing a key role in regulating
effector T cell function and responses to anti-PD-L1/PD-1
therapy. Thus, could be possible that the inactivation of CD28
costimulatory signaling may reproduce the suppressor effect
triggered by PD-1. PD-1 expressed in CD4+FOXP3+ Treg cells
plays a central role in regulating peripheral immune responses
(10, 12). During chronic infection, CD4+FOXP3+ Treg that
upregulate PD-1 showed a stronger suppressor function in mice
infected with lymphocytic choriomeningitis virus (12). Within
CD8+HLA-DR+ Treg cells, the high frequency of PD-1 strongly
suggests that it may be associated with their regulatory capacity.
In line with this, we found that an anti-PD-1 neutralizing
antibody abrogated their suppressor activity. Multiple evidences
seem to support that CTLA-4 and PD-1 receptors inhibit T
cell activation by diverse mechanisms (26). Whereas, CTLA-4
increases the threshold needed for T cell activation by competing
with CD28 co-receptor, PD-1 limits immune response at effector
T cell activity level, preferentially in peripheral tissues where
PD-L1 is expressed (8, 29, 30). Consequently, the immune
checkpoint blockade by anti CTLA-4 and anti PD-1/PDL1
specific antibodies also differs in its mechanism of action
(17).
An open question is whether manipulation of the PD-1/PD-
L1 pathway is preventing priming or exhaustion, instead of
reversing it. In the case of CD8+HLA-DR+ Treg cells, although
similar suppressor activity on CD4+ or CD8+ responder cells
was detected, we found that PD-1 neutralization specifically
abrogates the suppression capacity on CD8+ responder cells
with little effect on CD4+ responder cells, suggesting that PD-
1 blockade may preferentially affect CD8+ T cells. Moreover, the
similar behavior of PD-1, PD-L1, and CTLA-4 within CD4+ and
CD8+ responder cells during the co-culture rise the possibility
that a third population may be involved in their suppressor
mechanisms. For instance, the interaction between CD8+HLA-
DR+ Treg and APC during the suppression assay should be
further addressed, because the lack of reversion of the suppressor
effect on CD4+ responder cells could be related with the fact
that APC activate naïve CD4+ T cells in the early phase of
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the immune response, typically in lymph nodes, while CD8+ T
cells activation occurs later presumably improved by CD4+ T
cells help. This explanation seems to be in line with a previous
report of James Allison group (10) showing that anti- CTLA-
4, but not anti-PD-1, acts at the initial stage of naïve T-cell
activation, affecting CD4+ effector cells. Similarly, the same
group reported that CD4+ T cells suffer a preferential expansion
in CTLA-4(–/–) mice (31), and behave as key regulator in
maintaining T cell homeostasis of CD4 vs. CD8T cells (32).
Therefore, it was expected that in the present study anti-CTLA-4
in contrast with anti-PD-1 abrogates the suppression on CD4+
effector cells. To our knowledge, this is the first time that PD-
1 neutralization was shown to block the suppressor capacity of
a CD8+ Treg population, acting specifically on CD8+ effector
cells.
An additional feature of CD8+HLA-DR+ Treg cells is their
high proliferative capacity associated with increased frequency
of non-viable cells, meaning that they belong to a subset with
a high renewal rate. In concordance with a previous study
(33), we also found that highly proliferative CD8+HLA-DR+
showed a high frequency of PD-1+ cells. In addition, it was
previously reported that CD4+CD45RO+FOXP3+CD25hi
T lymphocytes were highly proliferative, compared
with memory CD4+CD45RO+FOXP3−CD25− or naive
CD4+CD45RA+FOXP3−CD25− populations (34). Similarly,
in inflamed skin CD4+ Treg were highly proliferative in
comparison with conventional memory T helper cells (35).
Of note, peripheral blood CD8+HLA-DR+ Treg with high
proliferative rate also possess a memory-like phenotype.
Regarding induced CD8+HLA-DR+ Treg cells, we also
showed that a subset of highly purified CD8+HLA-DR−
T cells can acquire the expression of HLA-DR. This is in
line with our previous report (5, 36), where we showed that
induced CD8+HLA-DR+ Treg cells sorted after PBMCs
activation behave as potent suppressor cells. The addition of
highly purified CD8+HLA-DR+ cells to responder PBMCs
not only induced suppression of proliferative CD3+ cells
but also induced preferential death of responder CD8+
cells without any significant effect on CD4+ T cells. This
effect was only slightly reversed after PD-1 neutralization,
indicating that other mechanism/s may be involved in apoptosis
induction. After activation, most CD8+HLA-DR+ Treg
express PD-L1. In addition to PD-1, PD-L1 can bind to
CD80 on activated CD8+ cells, triggering an apoptosis
signal (37).
There is an emerging concept that not all FOXP3+ Treg
are identical and may include distinct phenotypes specialized to
selectively regulate specific effector T cell responses and control
inflammation at defined anatomical tissue sites (38). For instance,
TIGIT can inhibit T cell responses by binding the ligand CD155
on dendritic cells (DCs) thereby inhibiting IL-12 while inducing
IL-10 production (39), or by directly inhibiting T cell activation
and proliferation (40–42). Similarly to CD8+HLA-DR+ Treg
cells, CD4+FOXP3+ cells with high suppressor function were
also associated with TIGIT expression (43), CTLA-4, and PD-
1 co-inhibitory molecules (39, 40), and within CD4+ TILs
almost exclusively detected on FOXP3+ Treg (11). CD8+HLA-
DR+ Treg also showed expression of CD155 TIGIT ligand. The
agonistic effect of the anti-TIGIT antibody we used prevented us
from observing abrogation of suppression by this antibody.
The expression of chemokine receptors may identify different
human Treg cell subsets (44, 45). Another important similarity
between CD4+FOXP3+ and CD8+HLA-DR+ Treg is the
expression of CCR4, previously associated with stronger
suppressor activity (43). In our case, CD8+HLA-DR+CCR4+
Treg cells showed augmented frequency and expression of PD-1
(data not shown). In line with the elevated expression of CCR4
and PD-1 on Treg cells, it was reported that treatment of T cells
with anti-CCR4 immunotherapy enhance not only CD4 but also
CD8 immune responses (46).
Exhausted T cells can be distinguished from T cell anergy
or senescence (47, 48). Anergy occurs during T cell priming by
inadequate costimulatory signals whereas senescence is growth
arrest after extensive proliferation. In contrast, exhausted T
cells arise from cells which initially gained effector function but
were gradually silenced due to continuous TCR stimulation by
a persistent antigen (49). High PD-1 expression is a hallmark
of “exhausted” T cells that have experienced high levels of
stimulation or reduced CD4+ T-cell help (18) as seen during
chronic infections and cancer. The principal characteristic of
exhausted T cells is loss of function in a hierarchical manner.
IL-2 production and ex vivo killing capacity are lost at the
early stage of exhaustion (18). Whereas, TNFα production is
lost at an intermediate stage, IFN-γ is lost at the advanced
stage of exhaustion (50). After a single round of anti-CD3
plus anti-CD28 activation, cord blood CD8+HLA-DR+ cells
acquire most of the inhibitory markers associated with exhausted
T cells while retaining their naïve phenotype. Therefore, it
was inappropriate to associate this Treg subset with exhausted
cells. Also, CD8+HLA-DR+ lack TIM-3 expression, and after
PBMCs stimulation showed increased frequency of IFN-γ and
TNFα positive cells and greater degranulation as revealed by
CD107a expression. In addition, granzyme B (GzmB), increased
in exhausted T cells (51), showed no differences between
CD8+HLA-DR− and CD8+HLA-DR+ T cells. All together,
these data strongly argue against CD8+HLA-DR+ Treg being
exhausted T cells.
Regarding biological implications of CD8+HLA-DR+ cells,
we observed that these Treg cells were present in TILs of patients
withNSCLC at even higher frequencies thanCD4+FOXP3+ Treg
cells (5). These results are supported by a report that TIGIT and
PD-1 were expressed by a large percentage of NSCLC-infiltrating
CD8+ T cells (52).
Overall, data presented in this study indicates that CD8+HLA-
DR+ Treg and CD4+FOXP3+ Treg share phenotypic
and functional features, and that they may be similarly
involved in the control of antitumor immune responses
and autoimmunity. Therefore, therapeutic strategies that
aim to overcome Treg activity as a means of enhancing
antitumor immune responses should integrate this novel
intratumoral subset of highly suppressive CD8+HLA-DR+ Treg
cells.
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